How the placenta affects maternal and fetal health
Official title: Placental Biology in Health and Disease
Run by University of Oxford · NCT07470320 · Data updated 2026-11-12
This project will test whether tiny particles released by the placenta differ in pregnancies with pre-eclampsia, gestational diabetes, or fetal growth restriction compared with healthy pregnancies and non-pregnant women.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | Women only |
| Enrollment | 1000 (estimated) |
| Sponsor | University of Oxford Academic / other |
| Locations | 1 site (Oxford) |
| Status | Recruiting |
| Started | December 16, 2025 |
| Main results expected | May 31, 2030 |
| Study ends | May 31, 2030 |
| Registry record updated | November 9, 2026 |
| Trial ID | NCT07470320 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include pregnant people with pre-eclampsia, gestational diabetes, fetal growth restriction, those at high risk for pre-eclampsia, healthy pregnant people, and healthy non-pregnant women willing to provide consent and samples at the Oxford site.
✕Probably not a fit
People whose pregnancy issues are caused by non-placental conditions or who cannot attend the single Oxford site are unlikely to benefit directly from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This single-site, non-interventional observational project collects blood and placental samples from pregnant people with pre-eclampsia, gestational diabetes, fetal growth restriction, predisposed pregnancies, healthy pregnancies, and non-pregnant controls. Laboratory analyses will focus on extracellular vesicles and soluble placental factors to characterize their number, contents, and signaling properties. Researchers will compare molecular signatures across groups to identify markers linked to placental dysfunction. The ultimate goals are to find biomarkers for earlier detection and molecular targets that could inform future treatments.
Why it matters
Potential benefit: If successful, the findings could enable earlier blood-based detection of placental problems and point to new targets for therapies that reduce maternal and fetal complications.
How similar studies have gone: Previous research has reported altered placental extracellular vesicles in pre-eclampsia and gestational diabetes, but translating those findings into clinical tests or treatments remains largely unproven.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Female, aged 18 years or above * Willing and able to give informed consent for participation in the study * Able to read and understand written and spoken English to comprehend study materials and give informed consent * Non-pregnant women in good general health OR pregnant women who fall into one of the following: * Healthy pregnancy * Pre-eclampsia (PET) - defined by clinical diagnostic criteria, including hypertension and proteinuria * Gestational diabetes mellitus (GDM) - diagnosed by standard glucose tolerance tests during pregnancy * Fetal growth restriction (FGR) - diagnosed based on fetal weight or Doppler abnormalities * Predisposed to PET - high-risk factors for PET such as maternal type 1 or type 2 diabetes, autoimmune diseases or multiple pregnancies Exclusion Criteria: * Non-pregnant participants with active health conditions that could confound study outcomes * Pregnant participants with conditions unrelated to PET, GDM or FGR that could influence EV profiles e.g. active infections or malignancies
Where it's running
-
Oxford University Hospitals NHS Foundation Trust
Oxford, United Kingdom Recruiting
Study contacts
- Study coordinator: Professor Manu Vatish
- Email: manu.vatish@wrh.ox.ac.uk
- Phone: +441865 221009
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Pre-eclampsia risk in pregnancies after oocyte donation
We will follow pregnant women who used donated eggs and women who used their own eggs to see if pregnancies after oocyte donation lead to a higher risk of pre-eclampsia.
-
Use of metformin to prolong pregnancy in preterm preeclampsia in the Netherlands
In pregnant people with preterm preeclampsia, this study tests whether metformin can help them stay pregnant longer compared with placebo.
-
Natural cervical ripening to delay pharmacological induction of labor
This pilot study tests whether nipple stimulation and membrane sweeping can help some pregnant people go into labor on their own without needing drugs.
-
Maternal insulin and fat metabolism in pregnancies at risk for preeclampsia and gestational diabetes
This project will try to see if insulin resistance and how the body burns fats early in pregnancy predict later preeclampsia or gestational diabetes in people at higher risk.
-
Gestational diabetes and health outcomes for mothers and babies
This project will follow pregnant women with gestational diabetes to see how the condition affects mothers and their babies during pregnancy, delivery, and early postpartum.
-
Pilot testing daily fermented poi to improve the maternal microbiome and lower gestational diabetes risk
This pilot will test whether eating one pound of fermented poi daily for four weeks can change the maternal microbiome and lower gestational diabetes risk for pregnant people in mid-pregnancy.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.